Goldman Sachs’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $128K | Buy |
91,411
+14,600
| +19% | +$20.4K | ﹤0.01% | 4830 |
|
|
2025
Q1 | $124K | Sell |
76,811
-58,485
| -43% | -$94.2K | ﹤0.01% | 4782 |
|
|
2024
Q4 | $170K | Buy |
135,296
+43,903
| +48% | +$55.3K | ﹤0.01% | 4700 |
|
|
2024
Q3 | $172K | Buy |
91,393
+51,115
| +127% | +$96.1K | ﹤0.01% | 4532 |
|
|
2024
Q2 | $298K | Buy |
40,278
+29,131
| +261% | +$216K | ﹤0.01% | 4218 |
|
|
2024
Q1 | $87.3K | Sell |
11,147
-4,333
| -28% | -$33.9K | ﹤0.01% | 4478 |
|
|
2023
Q4 | $78.6K | Sell |
15,480
-30,864
| -67% | -$157K | ﹤0.01% | 4499 |
|
|
2023
Q3 | $274K | Buy |
46,344
+32,405
| +232% | +$192K | ﹤0.01% | 4148 |
|
|
2023
Q2 | $103K | Sell |
13,939
-79,176
| -85% | -$587K | ﹤0.01% | 4559 |
|
|
2023
Q1 | $880K | Buy |
93,115
+83,025
| +823% | +$785K | ﹤0.01% | 3748 |
|
|
2022
Q4 | $107K | Buy |
10,090
+35
| +0.3% | +$373 | ﹤0.01% | 4659 |
|
|
2022
Q3 | $74K | Buy |
+10,055
| New | +$74K | ﹤0.01% | 4980 |
|
|
2018
Q2 | – | Sell |
-981
| Closed | -$11K | – | 4162 |
|
|
2018
Q1 | $11K | Buy |
+981
| New | +$11K | ﹤0.01% | 4167 |
|
|
2015
Q4 | – | Sell |
-3,178
| Closed | -$169K | – | 4462 |
|
|
2015
Q3 | $169K | Sell |
3,178
-1,440
| -31% | -$76.6K | ﹤0.01% | 3940 |
|
|
2015
Q2 | $367K | Buy |
+4,618
| New | +$367K | ﹤0.01% | 3569 |
|